BYSI moving on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate. BeyondSpring shares are trading higher after the company announced an exclusive commercialization and co-development agreement with Jiangsu Hengrui for Plinabulin in Greater China.
News 
Market Data 
Discover 
AI
